Comparative Efficacy of Seven Biologics for Chronic Rhinosinusitis With Nasal Polyps: A Network Meta‐Analysis
Allergy · 2026
DOI: 10.1111/all.70352 ↗At a glance
Netzwerk-Metaanalyse in Allergy, 2026. Written by Shenglong Xu and 3 co-authors. Institution: Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, People's Republic of China. Major MEDLINE topics: Rhinosinusitis, Nasal Polyps, Biological Products, Sinusitis. Cited 5 times so far (Crossref); 39 references.
Abstract (original language)
Background
Multiple randomized controlled trials (RCTs) of biologics for chronic rhinosinusitis with nasal polyps (CRSwNP) have expanded treatment options. This network meta‐analysis (NMA) aimed to synthesize available evidence to compare the efficacy of these biologics.
Methods
A systematic literature search was conducted. Primary outcomes were nasal polyp score (NPS) and nasal congestion score (NCS), while secondary outcomes included the 22‐item Sino‐Nasal Outcome Test score, loss of smell score, the University of Pennsylvania Smell Identification Test score, and the Lund–Mackay score. A Bayesian random‐effects NMA model was applied. Rank probabilities and mean differences were calculated to compare the biologics at Week 24 and at the end of follow‐up (> 48 weeks), and the probabilities that the top‐ranked biologic exceeded others by the between‐group minimal important difference (MID) were estimated.
Results
A total of 13 trials involving seven biologics were included. Dupilumab, stapokibart, and tezepelumab demonstrated more favorable efficacy profiles across NPS, NCS, and secondary outcomes compared with omalizumab, mepolizumab, depemokimab, and benralizumab, forming a distinct top tier. The probabilities of exceeding MID thresholds between these three biologics were generally low, suggesting limited clinically meaningful differences among them. Subgroup analyses showed no significant differences in treatment effects between patients with and without comorbid asthma or prior nasal surgery.
Conclusions
Dupilumab, stapokibart, and tezepelumab may be considered leading options for patients with CRSwNP. Nevertheless, additional head‐to‐head trials and real‐world studies are warranted to further validate these findings and inform optimal biologic selection.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, People's Republic of China.
- Beijing Laboratory of Allergic Diseases, Beijing Municipal Education Commission, Beijing Key Laboratory of New Medicine and Diagnostic Technology Research for Nasal Diseases, Beijing Institute of Otolaryngology, Beijing…
- Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, People's Republic of China.
ORCID profiles: Luo Zhang
Cite
APA
Xu, S., Cai, S., Zhao, Y., & Zhang, L. (2026). Comparative Efficacy of Seven Biologics for Chronic Rhinosinusitis With Nasal Polyps: A Network Meta‐Analysis. Allergy. https://doi.org/10.1111/all.70352
Vancouver
Xu S, Cai S, Zhao Y, Zhang L. Comparative Efficacy of Seven Biologics for Chronic Rhinosinusitis With Nasal Polyps: A Network Meta‐Analysis. Allergy. 2026. doi:10.1111/all.70352
BibTeX
@article{Xu2026,
author = {Xu, Shenglong and Cai, Shiru and Zhao, Yan and Zhang, Luo},
title = {Comparative Efficacy of Seven Biologics for Chronic Rhinosinusitis With Nasal Polyps: A Network Meta‐Analysis},
journal = {Allergy},
year = {2026},
doi = {10.1111/all.70352}
}
EUVIMED